Exploring parental awareness and willingness to use monoclonal antibodies for respiratory syncytial virus prevention

Respiratory syncytial virus (RSV) remains a leading cause of severe illness in infancy, and the recent availability of new monoclonal antibodies such as nirsevimab presents an appealing prevention choice. Thus, this study investigated parental awareness, attitude, and acceptability to the application of monoclonal antibody treatment for prevention of RSV among parents in Jordan. In April-June 2025, 597 parents of children aged below 5-years old were surveyed via an online survey. Data analysis was performed using SPSS version 22, logistic regression being employed to examine predictors of acceptance by parents of monoclonal antibody treatment. Over half (330; 55.3%) were aware of RSV, the majority of whom were aware of the most obvious symptoms such as cough (301; 91.2%) and shortness of breath (298; 90.3%). Social media was the best source of information (82.1%). Awareness of monoclonal antibodies was minimal (144; 43.6%), but over half of those who were aware (91; 63.2%) were willing to have their child treated. Altogether, 381 parents (63.9%) believed monoclonal antibodies were effective, and 419 (70.2%) used pediatricians as their primary source of information. The study indicated that female parents, and those who reported believing in monoclonal antibodies effectiveness were more likely to report willingness to use treatment (AOR = 5.161, <i>p</i> < .001). Despite low awareness in general about RSV, parents have positive feelings toward monoclonal antibody injections, and professional, clear communications are critical with particular reference to mothers to increase acceptability and utilization of RSV prevention strategies in Jordan.